Los puntos clave no están disponibles para este artículo en este momento.
Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.
Building similarity graph...
Analyzing shared references across papers
Loading...
Donald A. Berry
Constance Cirrincione
I. Craig Henderson
JAMA
University of California, San Francisco
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Berry et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69d8e8a62c39562886ae3261 — DOI: https://doi.org/10.1001/jama.295.14.1658
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: